Krystal Biotech Inc expected to post a loss of 74 cents a share - Earnings Preview

Krystal Biotech

04/08/2023 19:39

* Krystal Biotech Inc  KRYS.OQ   KRYS.O  is expected to show
no
change in quarterly revenue when it reports  results on August 7
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Krystal Biotech Inc
is
for a loss of 74 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Krystal
Biotech
Inc is $140​, above​ its last closing price of $124.58. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -1.43       -1.44      -1.76     Missed  -22.3
 Dec. 31 2023  -1.31       -1.32      -1.25     Beat    5.4
 Sep. 30 2022  -1.23       -1.22      -1.17     Beat    3.9​
 Jun. 30 2022  -0.99       -1.02      -1.10     Missed  -8.3
 ​​Mar.        -1.06       -1.05      -0.99     Beat    5.6
 31 2022                                                
 Dec. 31 2021  -0.75       -0.73      -0.95     Missed  -29.7​
 Sep. 30 2021  -0.76       -0.74      -0.70     Beat    5.2
 Jun. 30 2021  -0.79       -0.76      -0.74     Beat    2.3
 This summary was machine generated August 4 at 18:39 GMT.  All
figures in US dollars  unless otherwise stated